47.80 +0.01 (0.02%)
Pre-Market: 8:03AM EDT
|Bid||47.25 x 2200|
|Ask||48.01 x 1000|
|Day's Range||46.88 - 48.04|
|52 Week Range||17.51 - 111.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||96.78|
Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22. On July 12, Advaxis stock closed at $1.22 and hit its 52-week low of $1.15. Advaxis hit its 52-week high of $7.45 on September 11, 2017. Today, the FDA lifted its clinical hold on Advaxis’s IND (Investigational New Drug) application for the initiation of its Phase 1/2 trial of a combination therapy of axalimogene filolisbac and AstraZeneca’s (AZN) Imfinzi (duravalumab).
For fiscal 2018, Nektar Therapeutics (NKTR) has recently raised its guidance to ~$1.1 billion, as the company will account for payments related to its Bristol Myers Squibb (BMY) collaboration in Q2 2018, which will end on June 30, 2018. The company will recognize the collaboration-related upfront payment of $1 billion in the quarter. On excluding these payments, Nektar Therapeutics maintained its full-year 2018 outlook range of $100 million to $110 million.
Nektar Therapeutics (NKTR) and Syndax Pharmaceuticals (SNDX) have entered a collaboration for the evaluation of the efficacy and safety of the combination therapy of Nektar’s CD122-biased agonist NKTR-214 and Syndax’s small molecule Class 1 specific HDAC inhibitor entinostat for the treatment of patients suffering from metastatic melanoma that have previously reported treatment progression with an anti-PD-1 (programmed death receptor-1) agent. The recently presented preclinical study results showed that the NKTR-214+entinostat combination therapy significantly inhibited tumor growth in kidney and colon cancers. The trial will focus on establishing the recommended dosage of the combination therapy in the Phase 1b stage.
Does Nektar's Stock Price Correction Signal a Good Opportunity? Nektar Therapeutics reported its biggest fall of ~42% on June 4 after the company reported preliminary results for its phase one and phase two trials for the company’s IO (immuno-oncology) candidate, NKTR-214, which was being evaluated in combination with Bristol Myers Squibb’s (BMY) Opdivo for the treatment of patients suffering from stage-IV metastatic melanoma, renal cell carcinoma, and urothelial cancers. BMY stock fell ~3% on the day.
On June 14, 2018, Nektar Therapeutics announced new study data for its opioid therapy drug NKTR-181 at the 80th Annual Scientific Meeting of the CPPD (College on Problems of Drug Dependence) in San Diego, California. Nektar Therapeutics’ NKTR-181 is a NME (new molecular entity) and the first analgesic opioid molecule to exhibit a reduced incidence of specific CNS-mediated side effects such as euphoria through the targeted alteration of brain-entry kinetics. According to Steve Doberstein, the senior vice president and chief research and development officer of Nektar, “We are privileged that these meaningful new data from our clinical trials, as well as our translational research, were recognized for oral presentation at the prestigious CPDD meeting.
On June 26, Isoplexis, a privately held life sciences company, and Nektar Therapeutics, announced a collaboration focused on the functional impact of Nektar’s NKTR-214 in the clinical setting at the single-cell level with the aim to reveal the mechanism and potential immune correlation with the outcome. The collaboration aims to employ Isoplexis’s IsoCode Chip’s single-cell functional profiling for profiling the effects of Nektar’s NKTR-214 drug in both monotherapy and combination treatments in a clinical setting. IsoPlexis’s chief executive officer, Sean Mackay, said, “We are excited to collaborate with Nektar Therapeutics and further demonstrate the broad impact of NKTR-214 and its ability to induce critical T cell responses in cancer immunotherapy.
On June 27, Nektar Therapeutics (NKTR) ended the trading day at a closing price of $46.25. On the day, NKTR stock was trading ~164% higher than the 52-week low of $17.51 it reported on August 21, whereas the stock was trading ~59% lower than the 52-week high of $111.36 it reported on March 12. Currently, NKTR stock is trading lower than its 50-day moving average of $67.63 and its 200-day moving average of $79.32.
Does Nektar's Stock Price Correction Signal a Good Opportunity? Nektar Therapeutics (NKTR) is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain. The company has entered a number of key collaborations recently to advance its drug pipeline.
On Tuesday, June 26, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: iBio Inc. (NYSE AMER: IBIO), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Nektar Therapeutics (NASDAQ: NKTR), and Oragenics Inc. (NYSE AMER: OGEN).
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / U.S. markets were mixed Friday, with the Dow snapping an eight day losing streak as energy shares rallied. However, major indexes experienced weekly losses on ...
NEW YORK, NY / ACCESSWIRE / June 18, 2018 / U.S. market plunged on Friday, but well-off session lows as investors appeared to look at previous signs of escalating trade tension between Washington and Beijing. ...
The S&P 500’s top gainers on June 14 were: Nektar Therapeutics (NKTR) gained 5.5%. Royal Caribbean Cruises (RCL) gained 5.1%. Comcast Corp A (CMCSA) gained 4.6%. Discovery Comm A (DISCA) gained 4.5%. Incyte (INCY) gained 4.4%. Nektar Therapeutics
Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...
Nektar Therapeutics (NKTR) went on a rollercoaster ride last week, and is down again today, following a downgrade, along with much of the rest of biotech. First, it notched a painful 40% plunge last Monday, in reaction to a presentation detailing its experimental drug NKTR-214 at a meeting at the American Society of Clinical Oncology, which didn't live up to high expectations. Then, it bounced back for two days of gains of 6.5% and 7.2% on Tuesday and Wednesday, respectively, before the optimism ran out and it fell more than 11% on Thursday. All of that movement means that while the intensely volatile shares are up 185% in the past 12 months, they've fallen more than 12% year to date. Today, the shares are down again, after H.C. Wainwright threw in the towel and downgraded Nektar to Neutral with a $54 price target.
The S&P 500’s top losses on June 7 were: Nektar Therapeutics (NKTR) declined 11.7%. Seagate Technology (STX) declined 5.9%. Lam Research (LRCX) declined 5.4%. J.M. Smucker (SJM) declined 5.4%. Advanced Micro Devices (AMD) declined 5%. Nektar Therapeutics
Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.
The Dow Jones industrial Average gained nearly 100 points even as everything else fell apart. The Nasdaq Composite, which had been rallied for four days, sank 0.7% to 7635.07, while the S&P 500 dipped 0.1% to 2770.37. "The Dow continued higher, but the NASDAQ Composite took a hit," writes Todd Market Forecast's Stephen Todd.
The S&P 500’s top gainers on June 6 were: Nektar Therapeutics (NKTR) gained 7.2%. Equifax (EFX) gained 6.1%. Dish Network (DISH) gained 5.8%. Devon Energy (DVN) gained 5.6%. Adv Micro Devices (AMD) gained 5.5%. Nektar Therapeutics
Nektar Therapeutics (NKTR) used up $52.5 million on operating activities in Q1 2018 compared with $34.6 million in Q1 2017. Operating cash flow in Q1 2018 included $57.5 million of net operating cash use along with $5 million for interest payments on Nektar’s senior secured notes partially offset by the receipt of a milestone payment of $10 million from Baxalta. Nektar expects cash used in operating activities in fiscal 2018 to increase as compared with fiscal 2017 mainly as a result of higher research and development expenses.
Nektar Therapeutics’ (NKTR) cost of goods sold increased from $6.1 million in Q1 2017 to $6.6 million in Q1 2018. This increase was due to Nektar’s clinical development of NKTR-214, NKTR-181, and NKTR-262 and preclinical activities for NKTR-255. Nektar Therapeutics expects research and development expenses to increase significantly in fiscal 2018 as compared to fiscal 2017 mainly on account of the development of NKTR-214 under its collaboration agreement with Bristol-Myers Squibb.
The Dow Jones Industrial Average gained more than 300 points today. Today, it was the Dow's turn. The Dow got a huge lift from Boeing (BA), which rose 3.2% to $371.56, and added 78.91 points to the price-weighted benchmark.
Nektar Therapeutics popped for the second day running Wednesday as it tried to recover from a melanoma presentation with Bristol-Myers Squibb.
In the first quarter of 2018, Nektar Therapeutics (NKTR) generated total revenues of $38 million compared with $24.7 million in the first quarter 2017. Nektar’s licensing and collaboration revenues rose more than 100% from $6 million in Q1 2017 to $13.7 million in Q1 2018. This increase was primarily due to the recognition of a milestone payment of $10 million received by Nektar in March 2018 resulting from the marketing authorization of Adynovi in the European Union in January 2018.